Physician profile
James Chiou
NPI 1770137853
$1,539.39
in general payments reported to CMS, 2019-2025
21 companies · $113 in 2025
The $113 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $589 · 2023: $366 · 2024: $362 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $367.32 | 2021-2024 | Xarelto |
| Inari Medical, INC. | $187.11 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $157.07 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $116.42 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.68 | 2022 | |
| Exact Sciences Corporation | $103.26 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $88.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.96 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $49.81 | 2022-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.31 | 2025 | Jardiance |
| Alkermes, INC. | $38.18 | 2023 | Vivitrol |
| Indivior INC. | $29.17 | 2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $23.55 | 2025 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $23.12 | 2025 | Rexulti |
| Abbvie INC. | $22.68 | 2023 | Mavyret |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21.36 | 2021 | |
| Abbott Laboratories | $20.75 | 2023 | Freestyle Libre |
| Lifescan, INC. | $19.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.71 | 2022 | |
| Ucb, INC. | $16.23 | 2023 | Cimzia |
| Baudax Bio INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chiou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.